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Abstract
While most epileptic patients respond to treatment with existing antiepileptic drugs, there remains a 
considerable  number  of  patients  in  whom  these  drugs  do  not  suffice.  Such  patients,  particularly 
children, are often treated using the ketogenic diet. This diet imposes a strict limit on carbohydrates; 
while providing for adequate protein,  most of the calories are supplied as triacylglycerol,  much of 
which is metabolized to ketone bodies. 
Animal  experiments  have provided evidence that  the anticonvulsant  effect  of  the ketogenic diet  is 
mediated by acetone and correlates with acetone levels. Acetone can be converted in vivo to glucose 
via  acetol  and  pyruvate;  the  initial  conversion  to  acetol  is  catalyzed  by  cytochrome  P450  2E1 
(CYP2E1).  When  CYP2E1 knockout  mice  are  subjected  to  starvation  to  induce  ketogenesis,  they 
develop  blood  acetone  levels  much  higher  than  those  observed  in  wild-type  mice.  Similarly, 
pharmacological inhibition of CYP2E1 significantly increases blood acetone levels in rat and man. 
Taken together, these observations suggest that pharmacological inhibition of CYP2E1 has the potential 
to  significantly  increase  the  antiepileptic  effect  of  the  ketogenic  diet.  With  patients  that  respond 
insufficiently to the diet  alone,  increased acetone levels may improve response.  With patients who 
respond sufficiently to the diet,  CYP2E1 inhibitors might allow relaxation of the fairly severe diet  
regimen and so improve compliance and quality of life. 
An existing inhibitor of CYP2E1 is the drug disulfiram. This drug also inhibits the enzyme aldehyde 
dehydrogenase, which functions in alcohol degradation, and in this capacity has long been used in the 
treatment of alcohol addiction. Disulfiram inhibits CYP2E1 at conventional therapeutic dosages and 
increases blood acetone levels in humans and animals. It should therefore be a viable candidate for the 
proposed drug/diet combination treatment. 
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Background
The blanket term “epilepsy” covers a fairly diverse range of conditions. This applies to their clinical 
manifestations; examples are the all-out grand mal seizures, focal seizures, which may affect only one 
limb or another, and absences, which do not involve any motor manifestations at all. It also applies to 
pathogenesis,  which  ranges  from biochemical  defects  in  transmitter  synthesis  or  degradation  over 
channel and receptor mutations to anatomical lesions. Lastly, and accordingly, it also applies to therapy. 
While drugs such as valproate and carbamazepine are useful in more than one form, no single drug is 
applicable in all forms and situations. Also, while some forms of epilepsy are more readily controlled 
by drug therapy than others, it seems that refractory cases occur across most forms.
A common motif in all epilepsies is an abnormally high level of neuronal excitability. In keeping with 
this observation, many antiepileptic drugs broadly inhibit neuronal activity, and accordingly are also 
used to lower CNS activity in situations ranging from psychoses to narcosis. Several such drugs, in 
particular the benzodiazepines and the barbiturates, are agonists of the GABAA receptor, one of the two 
major inhibitory ionotropic receptors in the brain. Valproate, apart from inhibiting sodium channels, 
also inhibits the degradation of GABA [1], and therefore indirectly increases GABAA receptor activity.
The ketogenic diet in the treatment of refractory epilepsy
The therapeutic effect of the ketogenic diet was discovered empirically, and its use actually predates the 
introduction of modern antiepileptic drugs  [2]. It has now largely been superseded by phenytoin and 
other anticonvulsant drugs. However, it remains in use in a significant number of patients, particularly 
in children, that fail to respond to anticonvulsant drug therapy. It is completely or partially effective in 
some, but not all of those patients; this applies across a range of different forms of epilepsy [3]. 
In the ketogenic diet, the greater fraction (according to  [2], between 75% and 83%) of all calories is 
supplied as triacylglycerol, while carbohydrates and protein are restricted. Carbohydrates yield glucose 
via degradation alone or via short adapter pathways, while most of the amino acids produced by protein 
breakdown can  be  used  for  gluconeogenesis.  Restricting  both  carbohydrates  and  protein  causes  a 
shortage of glucose. This is compensated by the breakdown of triacylglycerol to fatty acids, which are 
then converted to ketone bodies. The term comprises the two organic acids β-hydroxybutyrate and 
acetoacetate as well as acetone, which forms from acetoacetate through decarboxylation. Ketone bodies 
can partially replace glucose as a source of energy in most tissues, including the brain. 
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Role of acetone in the anticonvulsant effect of the ketogenic diet
Several alternative explanations have been proposed for the therapeutic effect of the ketogenic diet. In 
brain  tissue  slices,  acetoacetate  and  β-hydroxybutyrate  promote  opening  of  KATP channels  [4] and 
promote  the  presynaptic  accumulation  of  GABA  [5];  both  of  these  effects  might  reduce  neuronal 
excitability.  However,  recent  experiments  with  animal  models  of  epilepsy  point  to  acetone  as  the 
anticonvulsant mediator [6]. This conclusion is based on the following observations: 
1. Injection  of  acetone  alone,  in  the  absence  of  metabolic  ketogenesis,  is  sufficient  to  inhibit 
seizure activity [7]; the same is true of isopropanol, which is converted to acetone in vivo [8]. 
The  range  of  acetone  concentrations  required  for  anticonvulsant  activity  in  animal  models 
overlaps with that observed in patients on the ketogenic diet [9].
2. Like  several  anticonvulsant  drugs,  acetone  has  sedative  and  narcotic  properties  at  high 
concentrations [10, 11].
3. Acetoacetate, which is the precursor of acetone, has lower anticonvulsant activity than acetone; 
β-hydroxybutyrate, which is not converted to acetone, has none [12].
4. Metabolites of acetone (see Figure 1) have either weak anticonvulsant activity or none at all 
[13]. During ketosis, these metabolites do not occur in high concentrations in the blood [14, 15].
5. Using proton NMR, acetone has been detected as the major ketone body in the brain of epileptic 
children treated with the ketogenic diet [16].
The current proposal is based on the assumption that acetone mediates the anticonvulsant effect of the 
ketogenic diet. Animal studies that will be necessary to validate the proposed combination therapy will 
also help to further support the role of acetone, or refute it. Indeed, the use of CYP2E1 inhibitors has  
been suggested before as a touchstone to distinguish between acetone itself and its metabolites as the 
anticonvulsant mediators of the ketogenic diet [17].
Acetone metabolism
While textbooks sometimes describe it as a metabolic dead end of ketogenesis that is destined solely 
for exhalation and excretion, acetone actually undergoes significant metabolism in vivo. The details of 
this pathway have been elucidated in rats [18]. The initial hydroxylation of acetone to acetol is carried 
out by cytochrome P450 type 2E1 (CYP2E1; [19]), which is itself induced by ethanol and acetone [20, 
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21]. Acetol can then be converted to pyruvate via two alternative pathways (Figure 1). In the liver, 
pyruvate  produced  from  acetone  may  contribute  significantly  to  the  formation  of  glucose  via 
gluconeogenesis  [14, 22]; pyruvate formed in the brain would likely undergo further degradation by 
pyruvate dehydrogenase.
The importance of CYP2E1 in acetone metabolism has been confirmed in knockout mice, which, upon 
fasting-induced ketogenesis, develop plasma acetone levels that are several times higher than those 
observed in the parental strains [23]. Similar results were observed when CYP2E1 was inhibited with 
diallyldisulfide [24] or disulfiram [25, 26].
CYP2E1
Like many other cytochrome P450 enzymes,  CYP2E1 is  strongly expressed in  the liver.  It  is  also 
expressed in some areas of the brain, including the hippocampus. CYP2E1 is the key enzyme in the so-
called  microsomal  ethanol  oxidation  system,  which  contributes  to  the  degradation  of  ethanol  via 
acetaldehyde. CYP2E1 also degrades acetone, and in both the liver and the brain it is transcriptionally 
induced  by  both  ethanol  and  acetone  [27-31].  In  the  brain,  CYP2E1  participates  in  dopamine 
degradation  [32], but no major disturbance of dopaminergic function has been reported in CYP2E1 
knockout mice. 
CYP2E1 is  also involved in  the metabolism of  xenobiotics  such as acetaminophen,  isoniazid,  and 
aniline,  as  well  as  halothane  and enflurane  [30,  33].  Many of  the  resulting  metabolites  induce  or 
promote cancer, and pharmacological inhibition of CYP2E1 has been suggested as a means to obstruct 
this route to carcinogenesis [34, 35]. Induction of CYP2E1, with consecutively increased production of 
reactive oxygen species, has also been implicated in alcohol-induced [36] and fat-induced [37] forms of 
hepatitis.
The structure of CYP2E1, with two different inhibitors bound to it, has been solved [38], which opens 
the way to the development of specific inhibitors. An inhibitor of CYP2E1 that already is in clinical use 
is disulfiram. Inhibition of CYP2E1 occurs at dosages that are also used in the treatment of alcoholics;  
this is evident both from drug interactions and from disulfiram-induced acetonemia [25].
The rationale for supplementing the ketogenic diet with CYP2E1 inhibitors
While the ketogenic diet is effective in many epileptic patients, it still falls short in others; a significant 
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number of patients respond with only partial reduction of seizures or not at all [3, 39, 40]. Results from 
animal experiments [7, 12] suggest that consistent anticonvulsant action of acetone may require plasma 
levels that are not consistently obtained by the diet alone  [9]. It seems plausible that insufficiently 
treated patients should benefit from a further increase of diet-induced plasma acetone levels. Genetic 
and pharmacological studies [23, 25, 26] suggest that such higher, therapeutically more effective levels 
should be attainable by the proposed diet-drug combination. 
The ketogenic diet, while often effective, is hampered by limited patient compliance, which is due to its 
impact on the quality of life, as well  as medical issues such as growth failure, kidney stones, and 
osteoporosis  [41]. Accordingly, less rigid dietary regimens are being explored [42]. It seems possible 
that combination with pharmacological inhibition of CYP2E1 would permit a relaxation of dietary 
regimens, while still maintaining acetone levels in the therapeutic range. Such a regimen could then 
improve compliance in patients who in principle respond satisfactorily to the diet alone, and potentially 
be a viable alternative for patients who respond to conventional anticonvulsant drugs but experience 
serious side effects from such treatment.
A candidate CYP2E1 inhibitor: disulfiram
Among the known inhibitors of CYP2E1, the only one in current clinical use is disulfiram, which is 
therefore the most obvious candidate for animal and clinical studies. Disulfiram was first characterized 
as an inhibitor of aldehyde dehydrogenase, and as such has been used for more than fifty years to  
prevent relapse in alcohol addicts.  Subsequently,  disulfiram was found to also inhibit  dopamine-β-
hydroxylase [43], CYP2E1 [44], and proteasomes [45]; novel applications based on these effects have 
been proposed [46]. The drug is metabolized rapidly, and it is the metabolites that are responsible for 
the  various  inhibitory  effects.  Due  to  its  widespread  and  longstanding  use  in  the  treatment  of 
alcoholics, the pharmacokinetics, pharmacodynamics, side effects, and drug interactions of disulfiram 
are well-tilled ground [30, 47-49].
Pharmacokinetics, metabolism
After oral uptake, disulfiram undergoes rapid and quantitative uptake and metabolism [48]. After initial 
reduction of disulfiram to diethyldithiocarbamate (DDTC), the latter undergoes methyl conjugation and 
repeated  oxidation (Figure 2).  Oxidation can be carried out  by several  different  cytochrome P450 
enzymes;  CYP2E1 itself  is  one  of  them,  but  not  as  efficient  as  several  others  [50].  Some of  the 
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metabolites are conjugated with glucuronic acid and excreted; a fraction of the sulfur contained in 
disulfiram is recovered in the urine as sulfate.
Most studies on disulfiram and its active metabolites concern the liver, because alcohol degradation 
occurs there. Since the brain lacks the liver’s abundance of P450 enzymes, it is not clear how efficient 
formation of the active metabolites in the brain may be.
Inhibition of aldehyde dehydrogenase (ADH)
Inhibition of ADH by disulfiram is the pharmacological rationale of its use in the treatment of alcohol 
addicts. Alcohol dehydrogenase converts ethanol to acetaldehyde, which in patients that have taken 
disulfiram accumulates and causes intense hangover-like symptoms (headaches, nausea, and vomiting). 
The  inhibition  of  aldehyde  dehydrogenase  is  caused  by  the  disulfiram  metabolite  S-methyl-N,N-
diethylthiolcarbamate sulfoxide (DETC-MeSO; Figure 2). Inhibition is irreversible and involves the 
formation of an N,N-diethylcarbamoyl adduct of the active site cysteine [51].
Aldehyde dehydrogenase also occurs in one of the two alternative degradation pathways for acetol 
(Figure  1).  The possibility that  this  would influence the proposed application of  disulfiram seems 
remote but cannot be entirely dismissed (see below).
Inhibition of CYP2E1
The  inhibition  of  cytochrome  P450  metabolism by  disulfiram  was  initially  noticed  through  drug 
interactions  [52,  53] and  later  assigned  to  CYP2E1  [44].  A  recent  study  identified 
diethyldithiocarbamate as the inhibitory metabolite; mass spectrometry indicated formation of a mixed 
disulfide between this metabolite and the apo-enzyme  [54]. However, in this study, enzyme activity 
could not be restored by reductive cleavage of the disulfide, suggesting that the enzyme had incurred 
additional changes, for example the binding of another metabolite to its prosthetic heme group. Spectral 
effects suggestive of the latter have been reported [53], although that early study did not differentiate 
between CYP2E1 and other P450 enzymes. In any event, inhibition of CYP2E1 is irreversible and 
virtually complete at dosages similar to those used in the conventional treatment of alcoholics [55, 56].
The inhibition of CYP2E1 by disulfiram has been exploited in experimental studies [57], but it appears 
not  to  have  been  used  with  therapeutic  intention.  In  both  humans  and  animal  models,  CYP2E1 
inhibition by disulfiram amplifies blood acetone levels induced by fasting [26, 58].
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Dual effect of disulfiram in acetone degradation
Both CYP2E1 and ADH participate in the degradation of acetone. In this pathway, CYP2E1 precedes 
ADH  (Figure  1),  and  its  inhibition  should  therefore  exercise  the  dominant  effect,  raising  the 
concentration of acetone and reducing that of downstream metabolites. As discussed above, inhibition 
of aldehyde dehydrogenase would only concern one of two alternative pathways downstream of acetol, 
suggesting  that  its  effect  will  likely  be  minor.  However,  a  significant  increase  of  the  levels  of 
downstream metabolites, relative to levels attained with the diet alone, cannot be entirely ruled out. It is 
not clear at present whether this would add to or detract from the intended clinical effect of disulfiram. 
If ADH inhibition should turn out to produce untoward consequences, it may be necessary to consider 
other inhibitors of CYP2E1 that do not interfere with ADH.
Toxicity
In keeping with its long-standing use in alcohol addiction, there is a considerable variety of known 
possible side effects of disulfiram. A survey of all reactions reported in a 20 year period in Denmark 
[47] found an overall incidence of adverse reactions between 1:200 and 1:2000 per treatment year, and 
a fatality rate of 1:25,000 per treatment year. The most frequent complication was liver toxicity; this 
may to some extent have been facilitated by preexisting alcohol-mediated liver damage. Neurological 
and psychiatric symptoms were the next most common.
Intriguingly, several cases of disulfiram-induced seizures have been reported [59, 60], and apparently in 
at least some of these, alcohol consumption or withdrawal (which also may trigger seizures) were not 
involved. A biochemical explanation has not been provided. As stated earlier, disulfiram also inhibits 
dopamine-β-hydroxylase,  the  enzyme  that  converts  dopamine  to  norepinephrine.  In  animal 
experiments,  disulfiram,  as  well  as  genetic  knockout  of  the  enzyme,  promotes  the  occurrence  of 
seizures after concurrent application of cocaine  [61], a powerful inhibitor of presynaptic reuptake of 
dopamine and norepinephrine. Whether or not the sporadic cases of disulfiram-induced seizures are in 
any way related to this experimental observation is unknown. 
If  the inhibition of dopamine-β-hydroxylase by disulfiram should indeed turn out to counteract its 
intended therapeutic effect, it may be necessary to develop more specific CYP2E1 inhibitors that do not 
interfere with dopamine-β-hydroxylase. If interference with dopamine degradation by CYP2E1 itself 
should present a problem, it may be alleviated by the use of inhibitors that are excluded by the blood 
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brain barrier.
Interaction of disulfiram with hyperbaric oxygen
In rats exposed to hyperbaric oxygen, disulfiram amplified oxygen-induced lung toxicity, which was 
ascribed to inhibition of superoxide dismutase [62]. The disulfiram dosages used in these experiments 
were far higher than those used therapeutically in humans.
Hyperbaric  oxygen  can  also  induce  seizures,  which  has  been  ascribed  to  inhibited  transport  and 
presynaptic depletion of GABA [63]. In keeping with this explanation, such seizures can be inhibited 
with GABAA receptor agonists  [64]. It  is interesting to note that the first metabolite of disulfiram, 
diethyldithiocarbamate (Figure 2), can also inhibit hyperbaric oxygen-induced seizures [65]. Whether 
or not this observation is related to the antiepileptic action mechanism of disulfiram proposed here has 
not been established.
Experimental studies
The  proposed  therapeutic  approach  needs  to  be  tested  in  animal  experiments  and,  if  these  are 
successful, in clinical studies.
Animal experiments
These should be performed with established pharmacological mouse or rat models of epilepsy. The 
following experiments should be performed:
1. Wild  type  and  CYP2E1  knockout  mice  should  be  subjected  to  diet  regimens  varying  in 
stringency, with or without added disulfiram. Blood levels of acetone and its metabolites should 
be  monitored.  Behavioral  and  neurological  performance  scores  should  be  recorded,  and 
tolerable diet/disulfiram regimes should be established.
2. The effect of different diet/disulfiram combinations on experimentally induced seizure activity 
should be determined and compared against diet alone and disulfiram alone. CYP2E1 knockout 
mice should again be included as controls in order to understand possible contributions from the 
effects of disulfiram on targets other than CYP2E1.
3. Toxicity: Since disulfiram is approved and widely used for the treatment of alcohol addiction, 
toxicity studies should not be necessary at this stage.
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Clinical studies
Given the longstanding use of disulfiram in its established application, it should be possible to limit  
toxicity studies and focus them on potential novel complications arising from its combination with 
ketogenic diet or, potentially, with other antiepileptic drugs. 
The effectiveness  of  the  proposed combination  treatment  needs  to  be  studied  in  various  forms  of 
epilepsy. Initial studies might be conducted with a group of patients who show a partial response to 
ketogenic diet alone, in whom it could be determined whether or not addition of disulfiram improves 
clinical response. If results are favorable, the studies could be extended to patients who fail to respond 
to the diet alone. In addition, a combination of disulfiram with a relaxed ketogenic diet could be tried in 
patients whose seizures are controlled well by a strict diet alone, but who do not tolerate the diet well  
due to psychological reasons or medical complications.
In current practice, some patients are treated with both antiepileptic drugs and ketogenic diet at the 
same time. Interactions between acetone and several antiepileptic drugs have been studied in a mouse 
model [66]. Acetone increased the antiepileptic activities of some anticonvulsants; the degradation of 
acetone  was  accelerated  by  several  drugs  as  well.  Overall,  no  unmanageable  interactions  were 
observed. It should be noted, however, that the concentrations of acetone were not very high; ketogenic 
diet in conjunction with CYP2E1 inhibition would likely result in higher concentrations, which may 
lead to more significant interactions. This question would also have to be addressed in clinical studies.
Conclusion
Clinical  and experimental  data  from the  literature  support  the  notion  that  the  effectiveness  of  the 
ketogenic diet in the control of epileptic seizures could be augmented by inhibitors of CYP2E1. An 
established and well-known drug with such activity is disulfiram. Animal experiments and, if these are 
successful, clinical studies to explore the validity of this concept seem justified.
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Legends for Figures
Figure 1: Metabolism of acetone, according to reference  [18]. Step 1 may occur spontaneously, but 
inducible acetoacetate decarboxylase activity has been reported, though no enzyme has been purified 
[67,  68].  Steps 2 and 7 are catalyzed by alcohol- and acetone-inducible cytochrome P450 activity,  
mostly CYP2E1. Step 5 is catalyzed by aldehyde dehydrogenase. The drug disulfiram inhibits both 
CYP2E1 and aldehyde dehydrogenase.
Figure  2: Structures  of  disulfiram and  two  of  its  metabolites.  Diethyldithiocarbamate  (DDTC)  is 
formed by glutathione-dependent reduction and inhibits CYP2E1 [54]. The second metabolite, S-ethyl-
N,N-diethylthiolcarbamate  sulfoxide  (DETC-MeSO),  inhibits  aldehyde  dehydrogenase;  several 
cytochrome P450 enzymes participate in its formation from DDTC [50].
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